Exchange: NASDAQ·Updated 08:09 AM EDT
NRIX logo

NRIXNurix Therapeutics Inc

$24.22
$0.04
(0.17%)
Pre-Market
Prev Close $24.26
EarningsJul 9
Mkt Cap$2.51B
Vol11,499.00
News
all
press releases
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.
Zacks
News Placeholder
More News
News Placeholder
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value...
Yahoo! Finance: News
News Placeholder
Nurix Stock Up 29% in a Month: Here's What You Should Know
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Zacks
News Placeholder
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks
News Placeholder
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
Canopy Growth (CGC) delivered earnings and revenue surprises of -199.82% and -2.47%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
News Placeholder
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
Company News for Jun 9, 2026
Companies In The News Are: CPB, FCEL, NRIX, WIX.
Zacks
News Placeholder
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
Zacks
News Placeholder
FDA Milestones Fueling Expansion
The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH
24-7 Market News
<
1
2
...
>

Advertisement|Remove ads.